Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. lowered its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 61.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,214 shares of the biotechnology company’s stock after selling 80,622 shares during the period. Edgestream Partners L.P.’s holdings in Exelixis were worth $1,192,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Capital Management Corp VA grew its stake in shares of Exelixis by 17.4% in the 1st quarter. Capital Management Corp VA now owns 459,780 shares of the biotechnology company’s stock worth $10,911,000 after purchasing an additional 68,185 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Exelixis by 155.8% during the first quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock valued at $2,374,000 after acquiring an additional 60,925 shares during the period. Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of Exelixis in the 1st quarter valued at approximately $1,216,000. Jupiter Asset Management Ltd. boosted its stake in Exelixis by 148.2% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock worth $53,817,000 after purchasing an additional 1,354,062 shares during the period. Finally, Blair William & Co. IL grew its position in Exelixis by 1.2% during the 1st quarter. Blair William & Co. IL now owns 758,969 shares of the biotechnology company’s stock worth $18,010,000 after purchasing an additional 8,953 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling

In related news, Director David Edward Johnson acquired 200,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was purchased at an average cost of $20.32 per share, for a total transaction of $4,064,000.00. Following the completion of the purchase, the director now directly owns 1,300,730 shares of the company’s stock, valued at approximately $26,430,833.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Exelixis news, Director George Poste sold 11,686 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56. Following the completion of the transaction, the director now directly owns 213,907 shares in the company, valued at $4,483,490.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Edward Johnson acquired 200,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were bought at an average price of $20.32 per share, with a total value of $4,064,000.00. Following the completion of the purchase, the director now directly owns 1,300,730 shares of the company’s stock, valued at $26,430,833.60. The disclosure for this purchase can be found here. Insiders sold a total of 30,896 shares of company stock valued at $660,677 over the last ninety days. 2.85% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of research analyst reports. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a report on Thursday, April 11th. HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. JMP Securities reissued a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research report on Wednesday, April 10th. Finally, Stephens started coverage on shares of Exelixis in a research report on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $26.13.

Exelixis Stock Performance

NASDAQ:EXEL remained flat at $22.60 during mid-day trading on Tuesday. The company had a trading volume of 138,116 shares, compared to its average volume of 2,054,565. The company has a fifty day moving average of $21.80 and a 200 day moving average of $22.17. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $24.34. The company has a market cap of $6.85 billion, a PE ratio of 35.31, a P/E/G ratio of 0.56 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The firm had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the company posted $0.12 EPS. The company’s quarterly revenue was up 4.0% on a year-over-year basis. Research analysts predict that Exelixis, Inc. will post 1.14 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.